PerkinElmer completed the acquisition of Nexcelom Bioscience from Ampersand Capital for $260m.

PerkinElmer, a biotechnology company, completed the acquisition of Nexcelom Bioscience, a provider of automated cell counting solutions, from Ampersand Capital, a middle-market private equity firm, for $260m. "Nexcelom was founded with the goal of assisting bench scientists by automating tedious and manual cell counting processes. Over the past eighteen years the company has worked closely with our customers to develop powerful tools to solve their complex challenges in rapidly developing cell-based assay and biomanufacturing markets. Ampersand's support and guidance over the past three years have been an important part of the Nexcelom story, and I feel fortunate to have had the opportunity to partner with them," Peter Li, Nexcelom Bioscience President and CEO.